Fudan University: Breast Neoplasms trials

The registry lists 260 Breast Neoplasms studies with Fudan University as lead sponsor. 117 are open to participants now and 0 have results posted.

Phase 1 12Phase 2 118Phase 3 50Phase 4 6No phase 87(a study in two phases counts in both)

Studies

Page 3 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Physical and Psychological Effects of Different Temperature-controlled Breast Prostheses on Patients With Breast CancerCompletedNCT03830294Not applicable
• FUSCC Refractory TNBC Umbrella (FUTURE)Status unknownNCT03805399Phase 1/2
• Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast CancerStatus unknownNCT03799692Phase 4
• Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast CancerStatus unknownNCT03799679Phase 4
• Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast CancerActive, not recruitingNCT03772353Phase 1/2
• 500mg Fulvestrant in HR+ MBCCompletedNCT03708432
• 500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AICompletedNCT03695341
• 500mg Fulvestrant Versus Exemestane in MBCCompletedNCT03575260
• Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer PatientsCompletedNCT03541863
• Hypofractionated PBI After BCS for Low-risk Breast Cancer PatientsCompletedNCT03411174Not applicable
• PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) PatientsStatus unknownNCT03251313Phase 1
• The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast CancerStatus unknownNCT03202862Phase 2
• Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast CancerStatus unknownNCT03151447Phase 1
• Metronomic PLD in Patients With Primary Endocrine Resistant ABCStatus unknownNCT03071926Phase 2
• Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast CancerCompletedNCT02980965Phase 3
• Fulvestrant 500mg in Patients With Advanced Breast CancerStatus unknownNCT02909361
• Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast CancerCompletedNCT02687490Phase 2
• Mutation of BRCA1/2 and Other Potential Genes in Triple-negative Breast CancerStatus unknownNCT02670668Not applicable
• TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA SignatureActive, not recruitingNCT02641847Phase 2/3
• Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 VariationsCompletedNCT02628613Phase 2
• Hypofractionated Whole-breast Irradiation With Simultaneously Integrated Boost For Early-Stage Breast Cancer After Breast-conserving SurgeryStatus unknownNCT02617043Phase 2
• Axillary Radiotherapy for Early Stage Breast Cancer With Limited Positive Sentinel Lymph NodesStatus unknownNCT02612012
• Platinum Rechallenge in Patients With Platinum-sensitive mTNBCStatus unknownNCT02607215Phase 2
• ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)CompletedNCT02546934Phase 3
• Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) PatientsTerminatedNCT02348281Phase 2
• Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)Status unknownNCT02341911Phase 2
• Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABCWithdrawnNCT02140437Phase 2
• A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast CancerCompletedNCT02137083Phase 2
• Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast CancerStatus unknownNCT01924078Phase 2
• Relationship Between Hypoxia and Endocrine Response in Human Breast CancerStatus unknownNCT01814449
• Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast CancerCompletedNCT01712893Phase 3
• Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) PatientsCompletedNCT01658033Phase 2
• A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)TerminatedNCT01655992Phase 3
• A Study of Famitinib Malate in HER2-negative Metastatic Breast CancerCompletedNCT01653574Phase 2
• A Study of Apatinib in Non-triple-negative Metastatic Breast CancerCompletedNCT01653561Phase 2
• A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast CancerCompletedNCT01550848Phase 2
• IL-6 and IL-8 Level of Blood and Pleural Effusion During Chemotherapy in Metastatic Breast CancerTerminatedNCT01543126
• Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective TrialStatus unknownNCT01528826Phase 2
• Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast CancerStatus unknownNCT01526512Phase 2
• Docetaxel With or Without Metronomic Cyclophosphamide as First Line Chemotherapy in Metastatic Breast CancerStatus unknownNCT01526499Phase 2
• Study of Arimidex and Radiotherapy SequencingStatus unknownNCT01402193Phase 3
• Whole Breast Irradiation With Intensity Modulated Radiotherapy and Simultaneously Integrated Boost for Early Stage Breast Cancer PatientsStatus unknownNCT01394575Phase 2
• Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)CompletedNCT01380808Phase 2
• Adjuvant AI Combined With ZoladexStatus unknownNCT01352091Phase 3
• Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer TherapyCompletedNCT01314833Phase 3
• Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)CompletedNCT01287624Phase 3
• Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)CompletedNCT01216111Phase 3
• Study of Apatinib in Metastatic Triple-Negative Breast Cancer PatientsCompletedNCT01176669Phase 2
• Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast CancerStatus unknownNCT01170143Phase 2
• A Combination of Abraxane and Cisplatin in Metastatic Breast CancerCompletedNCT01149798Phase 2
• Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast CancerCompletedNCT01069081Phase 2
• A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years OldCompletedNCT01026116Phase 3
• Dexrazoxane as a Protective Agent in Anthracycline Treated Breast CancerTerminatedNCT00955890Phase 2
• Computed Tomography (CT) Based Lymphatic Mapping and Localization of Sentinel Lymph Node in Breast Cancer PatientsStatus unknownNCT00952679Phase 3
• Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast CancerStatus unknownNCT00902954Phase 3
• Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)CompletedNCT00629148Phase 2
• Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBCCompletedNCT00601159Phase 2
• An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC)Status unknownNCT00589901Phase 2
• Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast CancerStatus unknownNCT00525642Phase 2/3
• Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone MetastasisCompletedNCT00524849Phase 2/3